Clinical Trial Detail

NCT ID NCT02320305
Title MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

melanoma

Therapies

MART-1 antigen

GLA-SE + MART-1 antigen

Age Groups: adult

No variant requirements are available.